Paveway™ PLUS Microbial Strain Development
Tailored, Customer-Centric Solutions to
E. coli Strain Development
Rapid entry into cGMP manufacturing with an effective process starts with choosing the right strain. Paveway PLUS is our innovative and proven technology for the efficient microbial expression of both soluble and insoluble therapeutic proteins, producing industry-leading titers.
Introducing Paveway PLUS Workflows
Using tailored, customer-centric solutions to E. coli strain development, Paveway PLUS delivers a proven, modular set of workflows for early microbial process development and supply of pre-clinical material.
Provides a fast, reliable, and cost-efficient route to lead strain selection with a primary focus on speed, product titer and solubility.
Provides a more comprehensive evaluation of purified product, generating additional product quality data to drive decision making and de-risk the overall development process. Focuses on both titer and product quality for scenarios where a more considered lead strain selection strategy is required.
To enable you to understand expression levels of similar candidates during early-stage development, we can perform multi-candidate assessments of E. coli expressed proteins with similar amino acid sequences.
Paveway PLUS Advantages
Well-proven panel of E. coli host strains selected for their excellent performance characteristics and their ability to express high titers of recombinant proteins at high cell densities in large scale fermentations.
Lead strain generation in as little as four weeks. Platform-based approaches combined with high-throughput robotics supports fast-track process definition and development, resulting in shorter timelines to the clinic and market.
High product titers from large scale E. coli microbial fermentations are generally understood to offer the potential of the lowest cost of goods of any biological expression system.
Highly versatile expression system for a wide range of recombinant proteins using cytoplasmic (soluble or insoluble) and periplasmic expression modalities. An optimal expression strategy can be designed for each individual protein. A new high-throughput solution is available for products expressed insolubly.
Recombinant strains created using the Paveway PLUS technology show very low levels of plasmid loss in the absence of antibiotic-based selection pressure. This enables you to develop antibiotic-free fermentation processes suitable for large-scale manufacturing without sacrificing yield or versatility.
Customer Success
Learn more about our Customer Success. Theriva Biologics, a long term customer of FUJIFILM Diosynth Biolotechnologies, cited the high efficiency and quality of the Paveway platform and FDB’s sustained high level of customer service within this paper.
Contact Us
Discuss which Paveway PLUS workflow is best for you
